Free shipping over €250 · Tracked, discreet delivery in Europe
UU library
Every peptide, mapped to the body.
160 compounds, from approved medicines to early research molecules. Each one filed by the system research looks at, with its regulatory status and the strength of the evidence behind it.
- Compounds
- 160
- Research summaries
- 39
- At UU
- 56
- Approved medicine71
Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.
- In clinical trials19
In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.
- Research compound53
Not approved as a medicine by the FDA or the EMA. Some are registered in individual countries. Supplied for laboratory research only.
- Cosmetic ingredient17
Used as a topical cosmetic ingredient. Cosmetic use is not a medicinal approval, and most evidence comes from manufacturer and small panel studies.
Reviewed October 2026
In the UU catalog
Researched, batch-tested, ready to ship.
Compounds UU carries that have a full research summary in the library.
19 compounds
Brain, mood & sleep1
Peptides studied for cognition, stress response, sleep architecture and the nervous system.
- In trials
NNZ-2591
Cyclic glycine-proline analogue
A synthetic analogue of a natural IGF-1 metabolite. In clinical trials for rare neurodevelopmental disorders.
Summary pending
Skin & hair1
Copper peptides, melanocortins and the signal peptides used in skin research and cosmetics.
- In trials
Dersimelagon
MT-7117
Oral MC1R agonist
An oral small-molecule MC1 receptor agonist. In clinical trials for erythropoietic protoporphyria.
Summary pending
Gut & weight11
Incretins, amylin analogues and gut peptides studied for appetite, glucose and body weight.
- In trialsAt UU
Cagrilintide
Long-acting amylin analogue
A weekly amylin analogue in clinical trials, alone and combined with semaglutide, for weight reduction.
Human trialsShop - In trialsAt UU
Retatrutide
LY3437943
GIP, GLP-1 and glucagon receptor agonist
A triple-receptor agonist in Phase 3 trials. Studied for weight reduction, type 2 diabetes and liver fat.
Early human dataShop - In trials
Amycretin
GLP-1 and amylin receptor agonist
A single molecule acting at both GLP-1 and amylin receptors. In clinical trials in oral and injected forms.
Summary pending - In trials
Apraglutide
Long-acting GLP-2 analogue
A weekly GLP-2 analogue in clinical trials for short bowel syndrome and intestinal graft-versus-host disease.
Summary pending - In trials
CagriSema
Amylin and GLP-1 combination
A fixed combination of cagrilintide and semaglutide in Phase 3 trials for obesity and type 2 diabetes.
Summary pending - In trials
Efpeglenatide
GLP-1 receptor agonist
A long-acting GLP-1 agonist studied in cardiovascular outcome trials in type 2 diabetes.
Summary pending - In trials
Glepaglutide
Long-acting GLP-2 analogue
A long-acting GLP-2 analogue studied in Phase 3 trials for short bowel syndrome.
Summary pending - In trials
Mazdutide
IBI362 · LY3305677
GLP-1 and glucagon receptor agonist
A dual agonist approved in China and in trials elsewhere. Studied for weight reduction and type 2 diabetes.
Summary pending - In trials
Pemvidutide
ALT-801
GLP-1 and glucagon receptor agonist
A dual agonist studied for obesity and liver fat in Phase 2 trials.
Summary pending - In trials
Petrelintide
Long-acting amylin analogue
A weekly amylin analogue in Phase 2 trials for weight management.
Summary pending - In trials
Survodutide
BI 456906
GLP-1 and glucagon receptor agonist
A dual agonist in Phase 3 trials for obesity and fatty liver disease.
Summary pending
Immune & airways3
Thymic peptides, antimicrobial peptides and complement inhibitors studied in immune research.
- In trials
Brilacidin
Defensin mimetic
A synthetic small molecule modelled on host defence peptides. Studied in trials for oral mucositis and infection.
Summary pending - In trials
LTX-315
Oncopore
Oncolytic peptide
A peptide derived from lactoferricin that disrupts tumour cell membranes. Studied in early cancer immunotherapy trials.
Summary pending - In trials
Nangibotide
TREM-1 inhibitor
A 12-residue peptide that blocks the TREM-1 inflammatory receptor. Studied in clinical trials in septic shock.
Summary pending
Muscle, bone & joint1
Peptides studied for tendon and muscle repair, bone formation and connective tissue.
- In trials
Thymosin beta-4
RGN-259
Actin-sequestering peptide
The full 43-residue protein that TB-500 is based on. Studied in clinical trials for dry eye and slow-healing wounds.
Summary pending
Heart & blood2
Vascular peptides, anticoagulants and the mitochondrial peptides studied in cardiac research.
- In trials
Enlicitide
MK-0616
Oral macrocyclic PCSK9 inhibitor
An oral macrocyclic peptide that blocks PCSK9. In Phase 3 trials for lowering LDL cholesterol.
Summary pending - In trials
Rusfertide
Hepcidin mimetic
A synthetic mimic of the iron hormone hepcidin. In Phase 3 trials for polycythaemia vera.
Summary pending
The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.